In castration-resistant prostate cancer, PSMA-targeted CAR-NK-92 cells combined with anti-PD-L1 or anti-PD-1 antibodies overcame IFN-γ-induced PD-L1-mediated resistance, improving tumor control [89]. Here, PDCD1 is linked to neoplasm.